Tumor News and Research

RSS

Protein abundant in embryonic stem cells offers a new cancer target

A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston.

1 Jun 2009

Interleukin-2 shows promise against advanced melanoma

A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.

1 Jun 2009

Model for new generation of blood vessels challenged

In-growth and new generation of blood vessels, which must take place if a wound is to heal or a tumor is to grow, have been thought to occur through a branching and further growth of a vessel against a chemical gradient of growth factors. Now a research team at Uppsala University and its University Hospital has shown that mechanical forces are considerably more important than was previously thought.

1 Jun 2009

Drug combo improves outcome for advanced non-small cell lung cancer

A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC).

1 Jun 2009

Chemotherapy combination outcomes differ for aged, younger colon cancer patients

The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients under 70 -- but not for those who are older, according to Mayo Clinic and Dana-Farber Cancer Institute scientists who will present their findings at the American Society of Clinical Oncology's (ASCO) annual meeting in Orlando, Fla.

1 Jun 2009

Bayer announces new data on novel anti-cancer compound

Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

1 Jun 2009

New pathology tests double sensitivity to detect bile duct and pancreatic cancers

Pancreatic cancer and bile duct cancer are difficult to diagnose and often fatal because they are discovered in the advanced stages of the disease. Researchers have developed new tests that double the ability to detect bile duct and pancreatic cancers, according to a Mayo Clinic study published in the June issue of Gastroenterology.

1 Jun 2009

Surgery not necessary for most late-stage colorectal cancers

A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don't require immediate surgery to remove the primary tumor in the colon. Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) presented their data at the American Society of Clinical Oncology Annual Meeting.

31 May 2009

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.

31 May 2009

New cellular targets for HIV drug development

Focusing HIV drug development on immune cells called macrophages instead of traditionally targeted T cells could bring us closer to eradicating the disease, according to new research from University of Florida and five other institutions.

27 May 2009

Experimental therapy uses immune system to boost cure rate in neuroblastoma

A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.

27 May 2009

Research offers insight into why some prostate cancer returns

The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.

27 May 2009

To spread, skin cancer attacks immune dendritic cells

Dendritic cells are the sentinels of the immune system. When they're alert and on guard, they will marshal the body's immunosoldiers, T cells, to battle at the sight of harmful pathogens. But some diseases, such as cancer, are able to escape their watchful eye. By knocking out or beguiling dendritic cells, they slip the defenses of the immune system and sack the unsuspecting body.

27 May 2009

Activated stem cells in damaged lungs could be first step toward cancer

Stem cells that respond after a severe injury in the lungs of mice may be a source of rapidly dividing cells that lead to lung cancer, according to a team of American and British researchers.

26 May 2009

Restricting carbohydrates may slow prostate tumor growth

Restricting carbohydrates, regardless of weight loss, appears to slow the growth of prostate tumors, according to an animal study being published this week by researchers in the Duke Prostate Center.

26 May 2009

Abraxane prolongs survival in metastatic breast cancer

Research from the Northwestern University Feinberg School of Medicine has found that a less toxic, solvent-free chemotherapy drug more effectively prevents the progression of metastatic breast cancer and has fewer side effects than a commonly used solvent-based drug.

26 May 2009

Future cancer care, can we afford it?

When a cancer patient and his or her doctor discuss the value of a treatment option, the conversation usually centers on a consideration of the treatment's medical benefits versus its possible side effects for the patient. Increasingly, however, as the already high costs of cancer care continue to rise, a full view of the patient's welfare must also take into account the economic impact of the treatment on the patient and his or her family.

26 May 2009

Discovery of biological markers that may indicate poor breast cancer prognosis

A team of researchers has found an association between breast cancer survival and two proteins that, when present in the blood in high levels, are indicators of inflammation.

26 May 2009

QIAGEN launches novel product enabling non-invasive prenatal diagnostics and cancer detection

QIAGEN today announced the launch of a novel product for extraction of free circulating fragments of tumor- and fetal-derived nucleic acids as well as viral nucleic acids in human blood. Scientists consider these DNA and RNA fragments to have great potential for the highly sensitive and non-invasive diagnosis of a wide range of diseases, including congenital disorders, malignancies such as colon and lung cancer, and infections.

From QIAGEN Manchester Limited 25 May 2009

Viral Genetics issued patent for novel cancer therapies

Biotechnology firm Viral Genetics, Inc. has been issued a patent for novel cancer therapies. The patent protects cancer drugs that have been tested in pre-clinical research studies in mice. Issued on March 31, 2009, the U.S. Patent Number is: 7,510,710. Additional patents directed at generic classes of the drugs are still pending.

22 May 2009